2004 US life science funding

NIH, NSF, BioShield budgets advancing briskly

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

In contrast with last year's federal budget boondoggle, which saw funding increases for key life science agencies frozen for nearly 5 months while partisan politics held sway, rapid progress is being made to pass budgets for fiscal year (FY) 2004, which begins October 1.

During the past 2 weeks, the House of Representatives approved appropriations for the National Institutes of Health (NIH) and the Department of Homeland Security (DHS), which includes funding for Project BioShield. Last week, a House appropriations subcommittee approved a 6.2% increase for the National Science Foundation (NSF), nearly twice the increase requested by the White House. NIH and BioShield funding in the House match the administration's requests.

The Senate this week will take up floor debate on DHS, and the full House Appropriations Committee will consider the NSF funding measure. But floor debate in the House on NSF and floor action in the Senate on NIH, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Ted Agres

    This person does not yet have a bio.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development